Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrolment for a phase 2b clinical trial of BPS-804 (Setrusumab) intended for the treatment of osteogenesis imperfect (OI), it was reported yesterday.
The product has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency for the product for OI, a form of brittle bone disease.
The investigational OI drug has also been accepted into the European Medicines Agency's Adaptive Pathways Program and was offered PRIority MEdicines (PRIME) designation.
The trial is a multi-centre, randomised, double-blind, dose-finding phase 2b study named ASTEROID and will assess the drug in a total of 112 adult patients across the United States and Europe, according to the company.
MIM Software Inc awarded US FDA's 510(k) clearance for molecular radiotherapy dosimetry
Immuno Concepts wins US FDA 510(k) clearance for the Histofluor Rodent Tissue Slides
Acurx Pharmaceuticals' C. difficile drug receives Fast Track designation from UD FDA